AF
STRO icon

Allworth Financial’s Sutro Biopharma STRO Stock Holding History

Allworth Financial’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$99 – 4174
2024
Q4 		$99 Buy
+5
New +$153 ﹤0.01% 3844
2023
Q1 		– Sell
-4
Closed -$331 – 3287
2022
Q4 		$331 Buy
+4
New +$278 ﹤0.01% 2721

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Allworth Financial's STRO Position: Q1 2025 in Review

Allworth Financial sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 5 shares — an estimated $99 sold.

Allworth Financial first reported a position in STRO in Q4 2022 and held it in 2 quarters. The position peaked at $331 in Q4 2022. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Allworth Financial reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Allworth Financial sold 5 Sutro Biopharma shares in Q1 2025, an estimated $99.
  • Allworth Financial first reported a position in Sutro Biopharma in Q4 2022 and held it in 2 quarters.
  • Allworth Financial's Sutro Biopharma position peaked at $331 in Q4 2022.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Allworth Financial's 13F filing for Q1 2025, filed 30 Apr 2025.